{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:24:56Z","timestamp":1793125496749,"version":"4.5.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec id=\"ab-coi220088-4\"><jats:title>Importance<\/jats:title><jats:p>Patients with cancer are known to have increased risk of COVID-19 complications, including death.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220088-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer compared to noncancer controls.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220088-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Retrospective population-based cohort study using linked administrative databases in Ontario, Canada, in residents 18 years and older who received COVID-19 vaccination. Three matched groups were identified (based on age, sex, type of vaccine, date of vaccine): 1:4 match for patients with hematologic and solid cancer to noncancer controls (hematologic and solid cancers separately analyzed), 1:1 match between patients with hematologic and patients with solid cancer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220088-7\"><jats:title>Exposures<\/jats:title><jats:p>Cancer diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220088-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Outcomes occurring 14 days after receipt of second COVID-19 vaccination dose: primary outcome was SARS-CoV-2 breakthrough infection; secondary outcomes were emergency department visit, hospitalization, and death within 4 weeks of SARS-CoV-2 infection (end of follow-up March 31, 2022). Multivariable cumulative incidence function models were used to obtain adjusted hazard ratio (aHR) and 95% CIs.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220088-9\"><jats:title>Results<\/jats:title><jats:p>A total of 289\u202f400 vaccinated patients with cancer (39\u202f880 hematologic; 249\u202f520 solid) with 1\u202f157\u202f600 matched noncancer controls were identified; the cohort was 65.4% female, and mean (SD) age was 66 (14.0) years. SARS-CoV-2 breakthrough infection was higher in patients with hematologic cancer (aHR, 1.33; 95% CI, 1.20-1.46; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) but not in patients with solid cancer (aHR, 1.00; 95% CI, 0.96-1.05; <jats:italic>P<\/jats:italic>\u2009=\u2009.87). COVID-19 severe outcomes (composite of hospitalization and death) were significantly higher in patients with cancer compared to patients without cancer (aHR, 1.52; 95% CI, 1.42-1.63; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Risk of severe outcomes was higher among patients with hematologic cancer (aHR, 2.51; 95% CI, 2.21-2.85; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) than patients with solid cancer (aHR, 1.43; 95% CI, 1.24-1.64; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). Patients receiving active treatment had a further heightened risk for COVID-19 severe outcomes, particularly those who received anti-CD20 therapy. Third vaccination dose was associated with lower infection and COVID-19 complications, except for patients receiving anti-CD20 therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-coi220088-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this large population-based cohort study, patients with cancer had greater risk of SARS-CoV-2 infection and worse outcomes than patients without cancer, and the risk was highest for patients with hematologic cancer and any patients with cancer receiving active treatment. Triple vaccination was associated with lower risk of poor outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.6815","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T16:32:23Z","timestamp":1672331543000},"page":"386","source":"Crossref","is-referenced-by-count":48,"title":["Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Inna Y.","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Vijenthira","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre\u2013University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Powis","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre\u2013University Health Network, Toronto, Ontario, Canada"},{"name":"Cancer Quality Lab (CQuaL), Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Calzavara","sequence":"additional","affiliation":[{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Patrikar","sequence":"additional","affiliation":[{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinku","family":"Sutradhar","sequence":"additional","affiliation":[{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Hematology\/Oncology, St Michael\u2019s Hospital\u2013Unity Health, Toronto Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Wilton","sequence":"additional","affiliation":[{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"},{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika K.","family":"Krzyzanowska","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre\u2013University Health Network, Toronto, Ontario, Canada"},{"name":"Cancer Quality Lab (CQuaL), Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada"},{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"ICES (formerly Institute for Clinical Evaluative Sciences), Toronto, Ontario, Canada"},{"name":"Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"25","key":"coi220088r1","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"16","key":"coi220088r2","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 breakthrough infections in vaccinated health care workers.","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"coi220088r3","doi-asserted-by":"publisher","first-page":"E132","DOI":"10.1002\/ajh.v97.4","article-title":"COVID-19 vaccine response in patients with hematologic malignancy: a systematic review and meta-analysis.","volume":"97","author":"Gong","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"coi220088r4","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer.","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"coi220088r5","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1470-2045(22)00202-9","article-title":"Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.","volume":"23","author":"Lee","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi220088r6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamaoncol.2021.5771","article-title":"Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US nationwide Veterans Affairs study.","volume":"8","author":"Wu","year":"2022","journal-title":"JAMA Oncol"},{"issue":"24","key":"coi220088r7","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/jama.2020.20323","article-title":"Uptake and accuracy of the diagnosis code for COVID-19 among US hospitalizations.","volume":"324","author":"Kadri","year":"2020","journal-title":"JAMA"},{"issue":"13","key":"coi220088r9","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1200\/JCO.21.02419","article-title":"Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative.","volume":"40","author":"Song","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi220088r10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021.","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"coi220088r11","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/j.clon.2020.11.006","article-title":"Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis.","volume":"33","author":"Zarifkar","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"coi220088r12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/jnci\/djaa168","article-title":"Clinical characteristics and outcomes of COVID-19-infected cancer patients: a systematic review and meta-analysis.","volume":"113","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"coi220088r13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1182\/blood.2021013768","article-title":"Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting.","volume":"139","author":"Mittelman","year":"2022","journal-title":"Blood"},{"issue":"2","key":"coi220088r14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"issue":"23","key":"coi220088r15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"issue":"7901","key":"coi220088r16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-022-04465-y","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.","volume":"603","author":"Liu","year":"2022","journal-title":"Nature"},{"issue":"10","key":"coi220088r17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ccell.2021.09.001","article-title":"Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies.","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"coi220088r18","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","article-title":"Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19.","volume":"8","author":"Haggenburg","year":"2022","journal-title":"JAMA Oncol"},{"key":"coi220088r19","doi-asserted-by":"publisher","first-page":"n1943","DOI":"10.1136\/bmj.n1943","article-title":"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study.","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"key":"coi220088r8","unstructured":"Updated eligibility for PCR testing and case and contact management guidance in Ontario. Published December 30, 2021. Accessed August 14, 2022. https:\/\/news.ontario.ca\/en\/backgrounder\/1001387\/updated-eligibility-for-pcr-testing-and-case-and-contact-management-guidance-in-ontario"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2800127\/jamaoncology_gong_2022_oi_220088_1678387706.0018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:02:43Z","timestamp":1678978963000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2800127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.6815","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}